Skip to main content
Loading

Tackling Mental Health through New Targets and Endpoints Progress

February 11, 2025
The October 2024 approval of the first schizophrenia drug with a new mechanism of action since the 1950s heralds an acceleration of investment interest in supporting new medicines for neuropsychiatric diseases. Companies pursuing new targets and working with patients or defining the most critical endpoints will explain opportunities for this still underserved space.​
Moderator
Boobalan Pachaiyappan, Managing Director, Senior Biotech Analyst - ROTH Capital
Speakers
Laxminarayan Bhat, CEO - Reviva Pharmaceuticals Inc
Srinivas Rao, Co-founder and CEO - atai Life Sciences
View all 2025 Program
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP